A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback